In the type 2 diabetes group, a total of 21 (88%) had changes in their diabetes therapy from baseline to follow up (insulin; sodium-glucose cotransporter 2 inhibitor (SGLT2i); glucagon-like peptide-1 receptor agonist (GLP1-RA); metformin) which might have influenced our results. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.